Purpose To generate and characterize a specific monoclonal antibody ( mAb ) against recombinant human RANK receptor and to develop an antiresorptive strategy using this mAb as an osteoclast-targeting platform that selectively targets osteoclast cells whilst delivering an attached ( i.e. chemically conjugated ) active drug cargo.